Neurotez

Neurotez

Early Stage

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Overview

Raised to Date: Raised: $15,952

Total Commitments ($USD)

Platform

Netcapital

Start Date

08/31/2022

Close Date

01/27/2023

Min. Goal
$10,000
Max. Goal
$500,000
Min. Investment

$100

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$4.00

Pre-Money Valuation

$45,272,228

Rolling Commitments ($USD)

Status
Funded
Reporting Date

01/30/2023

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$108

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Logos provided by Clearbit
Year Founded

2005

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B2C

Margin

Medium

Capital Intensity

High

Location

Bridgewater, New Jersey

Business Type

Growth

Company Website

Neurotez, with a valuation of $45.2 million, is raising funds on NetCapital. The company is developing a hormone replacement therapy named Memtin to treat Leptin deficiency in Alzheimer’s patients. The drug will help slow down cognitive decline in patients with Alzheimer’s and other forms of dementia. Neurotez has already received many rewards and recognitions and is backed by an excellent team of experts. Nikolaos Tezapsidis founded Neurotez in 2005. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $500,000. The campaign proceeds will be used for research and development, marketing, compensation for managers, and legal expenses.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$3,184

$1,250

 

 

Net Income

$-314,585

$-188,407

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$24,783

$5,882

Accounts Receivable

$0

$0

Total Assets

$169,799

$164,744

Short-Term Debt

$0

$65,356

Long-Term Debt

$62,255

$0

Total Liabilities

$62,255

$65,356
Financials as of: 08/31/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Neurotez 01/26/2023 Netcapital $45,272,228 $15,952 Equity - Common Funded RegCF
Neurotez 03/09/2022 StartEngine $44,870,036 $33,845 Equity - Common Funded RegCF
Neurotez 06/23/2021 Netcapital $21,959,058 $255,718 Equity - Common Funded RegCF
Neurotez 02/25/2018 Netcapital $24,544,690 $95,809 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Neurotez on NetCapital 2022
Platform: Netcapital
Security Type: Equity - Common
Valuation: $45,272,228
Price per Share: $4.00

Follow company

Follow Neurotez on NetCapital 2022
View on Netcapital (Closed)
Deal Analytics
Company Ratings
Deal Considerations

Buy Neurotez's Deal Report

Warning: according to the close date for this deal, Neurotez may no longer be accepting investments.

Neurotez Deal Report

Get KingsCrowd’s comprehensive report on Neurotez including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Neurotez is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Neurotez deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge